Funding Opportunity RFA-DE-20-007 from the NIH Guide for Grants and Contracts. To elucidate the capacity of cells residing in the postnatal DOC tissues to acquire developmental plasticity to undergo lineage reprogramming (trans-differentiation) in vivo in response to injury and other types of environmental stress, and to generate functionally-competent cells of alternative lineage(s).

Funding Opportunity RFA-HD-21-014 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites grant applications from institutions/organizations that propose to develop clinician-scientists and others who will be leaders in the field of pediatric clinical pharmacology research. Individuals in these programs should receive training and experience in the methods and conduct of basic and clinical research, in order to qualify them to perform such studies independently.

Funding Opportunity PAR-20-136 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages grant applications for support of the core functions of Cancer Epidemiology Cohorts (CECs), as well as methodological research. This FOA is intended to support maintenance of existing CECs infrastructure and resource sharing with broader scientific communities.

Notice NOT-OD-20-086 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HG-20-019 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for the establishment of a Technology Development Coordinating Center for the National Human Genome Research Institute (NHGRI). The Coordinating Center will be responsible for enhancing integration between components of the NHGRI Genome Technology program by facilitating opportunities for collaborations and leading efforts to promote standards in genomic technologies. The Center will also disseminate program advances, develop resources and outreach strategies for engaging the broader biomedical research community, and manage an Opportunity Funds program to rapidly fund and support promising small-scale work that advances the development of innovative genomic technologies.

Funding Opportunity PAR-20-131 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. With this FOA, the NCI intends to encourage submission of projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients' benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that employ mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally

Funding Opportunity RFA-HL-21-009 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks both applications from established sites of the Sickle Pan-African Research Consortium (SPARCO) and applications from other Sub-Saharan African nations to become the Consortiums new sites. The renewed and expanded SPARCO including a Clinical Coordinating Center (CCC), up to 3 established sites and additional satellite sites, up to 3 new sites, and the associated Sickle Africa Data Coordinating Center (SADaCC) will together constitute the Sickle Cell Disease (SCD) in Sub-Saharan Africa (SSA) Network. This network aims at developing a sustainable resource that will advance SCD-related epidemiologic, translational, and clinical studies.

Funding Opportunity RFA-HL-21-008 from the NIH Guide for Grants and Contracts. This limited competition Funding Opportunity Announcement (FOA) seeks an application from the current Sickle Africa Data Coordinating Center (SADaCC) to continue support of the activities of the renewed and expanded Sickle Pan-African Research Consortium (SPARCO), including the clinical coordinating center (CCC) in Tanzania, the 3 established sites in Ghana, Nigeria and Tanzania (and additional satellite sites), as well as up to 3 new Consortium sites located in additional sub-Saharan African nations. Together, these entities will constitute the Sickle Cell Disease (SCD) in Sub-Saharan Africa (SSA) Network. This network aims to develop a sustainable resource that will advance SCD-related epidemiologic, translational, and clinical research studies. The SADaCC application needs to propose a feasible and meritorious plan to provide overall project coordination, administration, data management, and biostatistical support of the SCD in SSA Network. In particular, this FOA seeks an application that plans for effective integration of SADaCC activities with those of SPARCO, the Consortium Sites, NHLBI, and review/monitoring bodies.

Funding Opportunity RFA-HL-21-007 from the NIH Guide for Grants and Contracts. This limited competition Funding Opportunity Announcement (FOA) seeks an application from the current Sickle Pan-African Research Consortium (SPARCO) Hub in Tanzania to continue coordinating, as the Clinical Coordinating Center (CCC), activities of the renewed and expanded Consortium (SPARCO), including the 3 established sites in Ghana, Nigeria and Tanzania as well as up to 3 new Consortium sites located in additional sub-Saharan African nations. Together, the CCC, the Sickle Africa Data Coordinating Center (SADaCC, see RFA-HL-21-008), as well as established and new sites of the Consortium (RFA-HL-21-009) will constitute the Sickle Cell Disease (SCD) in Sub-Saharan Africa (SSA) Network. This network aims to develop a sustainable resource that will advance sickle cell disease related epidemiologic, translational, and clinical research studies. The SPARCO CCC application needs to propose a feasible and meritorious plan for expanding a sickle hemoglobinopathy registry database that can facilitate patient tracking and follow-up and serve as a backbone for future SCD research. In particular, this FOA seeks an application that proposes to identify database elements and plans for harmonization of SCD phenotype definitions and ontologies, and integration of Collaborative Consortium activities with those of the DCC (SADaCC), NHLBI, Steering Committee, Observational Study Monitoring Board (OSMB), and existing training programs. The application needs to describe approaches to the development of regionally appropriate standards of SCD care, as well as approaches to the organization of research and clinical skill development activities. The application also needs to include coordination of Consortium sites to allow for development, implementation, and conduct of SCD cohort studies, as well as implementation research of preventive/ therapeutic practices.

Funding Opportunity PAR-20-137 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to phenotype and/or perform research on embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member. The mission of IMPC is to generate a comprehensive catalogue of mammalian gene function that will provide the foundation for functional analyses of human genetic variation. As of November 2019, the IMPC-KOMP2 KO mouse phenotyping effort has generated mutants in 9,051 mouse genes, completed phenotypes of 7153 lines, and released data for 6255 lines corresponding to 5861 mutant genes. Overall, the IMPC hopes to achieve broad-based phenotyping of roughly 20,000 KO strains. About 30% of these strains either are expected to be embryonic or perinatal lethal, or subviable. A large portion of homozygous lethal mutations are expected to have viable heterozygous phenotypes. The scientific community has the unique opportunity to leverage these mouse strains while they are being created and bred as part of the IMPC adult mouse phenotyping effort to perform additional in-depth phenotyping and research.

Funding Opportunity PAR-20-134 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to develop tools and devices that can continuously monitor a broader range of nutrients, metabolites and/or metabolic signals for advancing precision nutrition, microbiome, and circadian metabolism research.

Funding Opportunity RFA-AI-20-028 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select NIAID Emerging Infectious Diseases/Pathogens. Applications must include a Product Development Strategy attachment and demonstrate substantive investment by at least one industrial participant.

Funding Opportunity PAR-20-133 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support the development of tools/devices for sampling or monitoring of diet- GI (contents and mucosa) and microbial interactions (GI- Microbiome Explorer). It is anticipated that successful completion of the projects completed under this FOA will yield implementable devices/tools for gastroenterological research or other clinical applications, along with monitoring and sampling of GI contents and/or mucosa to examine diet-host-microbiome interactions for clinical research or diagnostic applications.

Funding Opportunity RFA-AG-21-019 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for P30 Alzheimer's Disease Research Centers (ADRCs). NIA-designated ADRCs serve as major sources of discovery into the nature of Alzheimers disease and Alzheimer's disease-related dementias (AD/ADRD) and into the development of more effective approaches to prevention, diagnosis, care, and therapy. They contribute significantly to the development of shared resources that support dementia-relevant research, and they collaborate and coordinate their research efforts with other NIH-funded programs and investigators.

Funding Opportunity RFA-HD-21-010 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity announcement (FOA) is to advance the field of population dynamics research by increasing research impact, innovation, and productivity; developing junior scientists; and maximizing the efficiency of research support.

Notice NOT-AG-20-017 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-20-006 from the NIH Guide for Grants and Contracts. This FOA encourages applications from institutions that propose to establish research experiences in kidney technology development. Successful programs should include a collaborative capstone research or design project(s), innovative and/or ground-breaking technology development, multidisciplinary/interdisciplinary teamwork, education in entrepreneurship, product development and navigating regulatory pathways, and clinical immersion. The intent of this FOA is to recruit undergraduate students as participants and to engage students from engineering and technical domains, but applicants may also propose the inclusion of medical students, graduate students and/or dual-degree students (e.g., M.D./Ph.D.; Pharm.D./Ph.D.) prior to their qualifying exams and selection of Ph.D. mentor.

Notice NOT-NS-20-042 from the NIH Guide for Grants and Contracts

Notice NOT-CA-20-031 from the NIH Guide for Grants and Contracts

Notice NOT-TR-20-008 from the NIH Guide for Grants and Contracts